| scholarly article | Q13442814 |
| P50 | author | Nicholas P J Day | Q28033668 |
| Tran Tinh Hien | Q30004272 | ||
| Sasithon Pukrittayakamee | Q30089895 | ||
| Jeremy Farrar | Q15967402 | ||
| Nicholas John White | Q21166848 | ||
| François Nosten | Q28033645 | ||
| Richard Price | Q42591886 | ||
| Sornchai Looareesuwan | Q59505994 | ||
| Piero Olliaro | Q72250873 | ||
| Karen I. Barnes | Q73446882 | ||
| Mayfong Mayxay | Q79073464 | ||
| Frank Smithuis | Q91619984 | ||
| Jean-Paul Guthmann | Q111077097 | ||
| Hla Yin Myint | Q114323022 | ||
| Martin Adjuik | Q114780677 | ||
| Kasia Stepniewska | Q30112539 | ||
| P2093 | author name string | Walter R J Taylor | |
| P2860 | cites work | Assessment of the pharmacodynamic properties of antimalarial drugs in vivo | Q24670346 |
| Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial | Q39564872 | ||
| Chloroquine versus sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum malaria in Savannakhet Province, Lao People's Democratic Republic: an assessment of national antimalarial drug recommendations | Q40549037 | ||
| Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil | Q40569553 | ||
| The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria | Q40573522 | ||
| Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children | Q40594441 | ||
| Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children | Q40618842 | ||
| Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria | Q40636345 | ||
| Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria | Q40642165 | ||
| Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria | Q40678753 | ||
| Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria | Q40680523 | ||
| A randomized comparison of oral chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Laos | Q41913836 | ||
| Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. | Q41914794 | ||
| Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia | Q41916246 | ||
| High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations | Q41916249 | ||
| The efficacy of chloroquine for the treatment of acute, uncomplicated, Plasmodium falciparum malaria in Laos | Q41916749 | ||
| Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. | Q41916847 | ||
| Sulphadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age. | Q41917325 | ||
| Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy | Q42668687 | ||
| Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria | Q42689734 | ||
| Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum | Q43801610 | ||
| Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study | Q43951050 | ||
| Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial | Q43972330 | ||
| Artesunate combinations for treatment of malaria: meta-analysis | Q44728450 | ||
| Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria | Q46170750 | ||
| Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria | Q47837231 | ||
| Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy | Q47842564 | ||
| Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand | Q47843085 | ||
| Risk factors for gametocyte carriage in uncomplicated falciparum malaria. | Q47849874 | ||
| Antimalarial drug resistance and mortality in falciparum malaria | Q47852651 | ||
| Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy | Q47866114 | ||
| Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination | Q48009282 | ||
| Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria | Q48012248 | ||
| Mefloquine in infants and young children | Q48035075 | ||
| Impact of chloroquine resistance on malaria mortality. | Q54121783 | ||
| Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group | Q67257399 | ||
| Chemotherapy of malaria | Q73780208 | ||
| A molecular marker for chloroquine-resistant falciparum malaria | Q31921233 | ||
| Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. | Q33690621 | ||
| Making malaria-treatment policy in the face of drug resistance | Q33735489 | ||
| Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria | Q33929311 | ||
| Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria | Q33980472 | ||
| Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria | Q34937320 | ||
| The assessment of antimalarial drug efficacy | Q34960538 | ||
| Factors contributing to anemia after uncomplicated falciparum malaria. | Q35112361 | ||
| Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy | Q35143090 | ||
| Monitoring antimalarial drug resistance: making the most of the tools at hand | Q35541782 | ||
| A systematic overview of published antimalarial drug trials | Q35667922 | ||
| Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. | Q35819658 | ||
| Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine | Q36794193 | ||
| Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies | Q36794389 | ||
| A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand | Q36874970 | ||
| Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study | Q37261150 | ||
| Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial | Q38883517 | ||
| Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria | Q38884349 | ||
| Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria | Q39164481 | ||
| Contribution of humoral immunity to the therapeutic response in falciparum malaria | Q39229106 | ||
| The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy | Q39234325 | ||
| Mefloquine-resistant falciparum malaria on the Thai-Burmese border | Q39234433 | ||
| The detection and treatment of Plasmodium falciparum malaria: time for change. | Q39309819 | ||
| Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers | Q39356303 | ||
| Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria | Q39370925 | ||
| Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. | Q39465436 | ||
| The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. | Q39472395 | ||
| Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens | Q39473852 | ||
| Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria | Q39517603 | ||
| High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. | Q39517612 | ||
| Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial | Q39532221 | ||
| Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria. | Q39553520 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium falciparum | Q311383 | ||
| Plasmodium falciparum malaria | Q18554672 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 4271-4280 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up | |
| P478 | volume | 48 |
| Q30483123 | A database of antimalarial drug resistance |
| Q28477853 | A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial |
| Q28474447 | A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy |
| Q26786586 | A systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malaria |
| Q36782415 | Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up |
| Q41912334 | Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola |
| Q43945037 | Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania. |
| Q35218484 | Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study |
| Q36681333 | Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria |
| Q34622342 | Artemisinin Antimalarials: Preserving the "Magic Bullet" |
| Q31151729 | Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials |
| Q24245639 | Atovaquone-proguanil for treating uncomplicated malaria |
| Q24234168 | Azithromycin for treating uncomplicated malaria |
| Q21090072 | Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment |
| Q24245920 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria |
| Q36505813 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review |
| Q37611543 | Competition and the evolution of reproductive restraint in malaria parasites |
| Q35101269 | Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar |
| Q36338542 | Delayed Plasmodium falciparum clearance following artesunate-mefloquine combination therapy in Thailand, 1997-2007. |
| Q36855449 | Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children |
| Q36201223 | Drug resistance hampers our capacity to roll back malaria |
| Q48022958 | Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial |
| Q28535686 | Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies |
| Q38065917 | Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies |
| Q43947607 | Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania |
| Q41945132 | Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali |
| Q39736943 | Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad |
| Q24812384 | Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies |
| Q37257937 | Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial |
| Q35220039 | Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo |
| Q40516074 | Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine |
| Q37121532 | Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa |
| Q24680404 | Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria |
| Q37641492 | Gancidin W, a potential low-toxicity antimalarial agent isolated from an endophytic Streptomyces SUK10 |
| Q35667005 | Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort |
| Q33446846 | Malaria: uncomplicated, caused by Plasmodium falciparum. |
| Q37172554 | Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria |
| Q35127949 | Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. |
| Q33351939 | Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants |
| Q39278723 | Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness |
| Q37225083 | Monitoring antimalarial drug efficacy: current challenges |
| Q28483969 | More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects |
| Q91693331 | Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand-Myanmar Border |
| Q38870446 | Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa |
| Q24649683 | Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey? |
| Q28487881 | Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar |
| Q33385477 | Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria |
| Q36691877 | Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria |
| Q42617661 | Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges |
| Q24244592 | Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria |
| Q24246263 | Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria |
| Q34983307 | Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda |
| Q34413590 | Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial |
| Q47244112 | Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges |
| Q36138872 | The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam |
| Q41540119 | The rationale and plan for creating a World Antimalarial Resistance Network (WARN). |
| Q37366389 | Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia |
| Q33276757 | Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison |
| Q38664529 | Use of quantitative pharmacology tools to improve malaria treatments |
| Q29619167 | Vivax malaria: neglected and not benign |
| Q36037701 | World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs |
| Q37396146 | dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo |
Search more.